Fibromyalgia exists in every country where researchers have looked for it. The condition affects an estimated 2% to 8% of the world’s population, with cases documented across North America, Europe, Asia, Latin America, and Africa. What varies dramatically from country to country is not whether fibromyalgia occurs, but how often it gets recognized, how quickly it gets diagnosed, and how seriously the medical community takes it.
Global Prevalence Rates
Fibromyalgia affects up to 5% of the world’s population, with women accounting for the majority of diagnosed cases. In clinical settings, women make up 80% to 96% of diagnosed patients, though population-level surveys suggest the gap between sexes is narrower than it appears in doctor’s offices: roughly 4% of women and 2.4% of men meet the criteria when screened broadly. The discrepancy likely reflects differences in who seeks care and who gets taken seriously when reporting widespread pain.
Rates vary considerably by region. In South Korea, prevalence sits around 2.2%. Japan reports 2.1%. In parts of mainland China, early studies using older diagnostic criteria found rates as low as 0.03% to 0.12%, though a study in Hong Kong placed it closer to 0.82%. European countries generally report higher prevalence, and Latin American nations tend to fall somewhere in between, though direct comparisons are tricky because studies use different diagnostic criteria and survey methods.
Why Rates Look So Different Across Countries
The wide range in reported prevalence, from under 1% in parts of China to several percent in Europe and the Americas, does not necessarily mean fibromyalgia is rare in some populations. Several factors push the numbers around.
Diagnostic criteria matter enormously. The original 1990 guidelines from the American College of Rheumatology required a physician to physically press on 18 specific tender points. Newer criteria, revised in 2010, 2011, and again in 2016, use symptom questionnaires covering widespread pain, fatigue, and cognitive difficulties. Countries that adopted the newer criteria tend to identify more cases. Studies using the older tender-point exam consistently produce lower numbers.
Cultural attitudes toward pain reporting also play a role. Researchers studying fibromyalgia in China have noted that cultural norms may discourage self-reporting of pain and other health complaints. They’ve also raised the possibility that diet, family structure, earlier retirement ages for women, and lower workplace stress could genuinely reduce the condition’s burden in some populations. Separating true differences in disease rates from differences in willingness to report symptoms remains one of the biggest challenges in global fibromyalgia research.
Diagnosis Takes Longer in Some Regions
Even where fibromyalgia is officially recognized, the path to diagnosis can be painfully slow. A survey comparing patients in Latin America (Mexico, Venezuela, and Brazil) with those in Europe found that Latin American patients lived with symptoms for an average of about 8.4 years before receiving a diagnosis, compared to roughly 7 years for European patients. Latin American patients also saw more doctors along the way: 5.4 physicians on average versus 4.0 in Europe.
This isn’t because Latin American doctors are less aware of the condition. In fact, physicians in that region were more familiar with the diagnostic guidelines than their European counterparts. The delay likely reflects differences in healthcare access, referral pathways, and competing medical priorities in each country’s health system.
Fibromyalgia in Africa
Research from sub-Saharan Africa is only beginning to emerge. The first study of fibromyalgia in the Democratic Republic of Congo, conducted at the University Hospital of Kinshasa, found that about 10.8% of patients attending the rheumatology clinic met the diagnostic criteria. That aligns with data from other parts of the world showing fibromyalgia in 10% to 20% of rheumatology patients globally.
The researchers described significant barriers to diagnosis in the Congolese setting: lack of physician awareness, skepticism about the condition’s legitimacy, unnecessary surgeries and heavy diagnostic workups chasing other explanations, and a tendency to redirect patients toward psychiatry rather than treat their pain. Studies from Morocco and Benin have documented similar patterns, with patients reporting feelings of injustice about their care and high rates of anxiety and depression complicating the picture. These challenges are not unique to Africa, but they’re amplified in healthcare systems with fewer specialists and limited resources for chronic pain management.
Official Medical Recognition
Fibromyalgia has a formal place in the international medical coding systems used by hospitals and insurers worldwide. In the ICD-10 system (the classification most countries currently use), it’s coded as M79.7. In the newer ICD-11, adopted by the World Health Assembly in 2019, fibromyalgia falls under the broader category of chronic widespread pain (MG30.01) but remains identifiable with its own specific code. This means that in any country using WHO diagnostic classifications, fibromyalgia is an officially recognized condition that doctors can diagnose and document.
That said, having a code in a classification system and having a medical culture that embraces the diagnosis are two different things. The Kinshasa study bluntly described fibromyalgia as “a controversial and often underreported clinical entity in routine medical practice,” and that description applies in varying degrees across every continent. Even in countries with well-established rheumatology infrastructure, some physicians remain skeptical, and patients frequently describe years of being dismissed before someone names what they’re experiencing.
Urban Versus Rural Differences
Within countries, geography can also shape who gets diagnosed. A large Spanish prevalence study in 2000 found that living in a rural area was one of the strongest predictors of having fibromyalgia, alongside being female and having other chronic conditions. A follow-up study in 2016, however, found no significant link between rural living and fibromyalgia rates. The earlier finding may have reflected poorer access to healthcare in rural areas, leading to more unmanaged chronic pain, or it may have captured real differences in physical labor demands and mental health burdens. Research has consistently shown that rural populations report more symptoms of anxiety and depression, both of which overlap heavily with fibromyalgia.
When researchers in Spain directly compared rural and urban fibromyalgia patients on clinical measures, they found almost no differences in symptom severity or demographics. The one exception was education level: urban patients had completed more schooling on average. This suggests that once fibromyalgia develops, the experience of the condition is largely the same regardless of where you live.
What the Global Picture Tells Us
Fibromyalgia is not a Western condition, an American condition, or a condition limited to wealthy nations. It appears everywhere researchers have systematically looked for it. The countries reporting the lowest rates tend to be the ones with the fewest studies, the oldest diagnostic criteria, or the strongest cultural barriers to reporting chronic pain. As awareness grows and newer, questionnaire-based diagnostic methods spread, prevalence estimates in underreporting regions will almost certainly rise. The condition’s biology does not respect national borders. What varies is whether the healthcare system in a given country is set up to find it, name it, and treat it.